Pharmaceutical

AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

Dec 13, 2024 - 06:00
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy
AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.
Read the original article

Tags:

Previous Article

Novocure’s Wearable Therapy Shows Promise in Treating Pancreatic Cancer, Phase 3...

Next Article

Risk adjusted net present value: What is the current valuation of Rallybio’s RLY...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eli Lilly tries a rare tactic: competing on price

Eli Lilly tries a rare tactic: competing on price

Nov 9, 2023

Opinion: The Alabama IVF ruling uses faux scientific language to justify a religious position

Opinion: The Alabama IVF ruling uses faux scientific la...

Feb 23, 2024

Novo Nordisk and Aspect join forces for bioprinting tissue therapeutics

Novo Nordisk and Aspect join forces for bioprinting tis...

Apr 12, 2023